抗体偶联药物（antibody–drug conjugate，ADC）是一类由单克隆抗体通过化学接头共价连接细胞毒性药物形成的新型生物治疗药物。ADC利用单克隆抗体将细胞毒性药物递送至肿瘤细胞，实现了对肿瘤细胞的精准杀灭，具有靶向性强和不良反应小的优势。美国FDA批准上市的15款ADC中，有3款用于治疗乳腺癌。此文主要对近年来应用于乳腺癌治疗的ADC的研究进展作一综述。

Antibody–drug conjugates (ADCs) are a new class of biological therapy drugs that covalently connect cytotoxic chemotherapy drugs with monoclonal antibodies through chemical linkers. ADCs use monoclonal antibodies to deliver cytotoxic drugs to tumor cells, achieving accurate killing of tumor cells, with the advantages of strong targeting and low adverse reactions. FDA has approved 15 ADCs for marketing, of which 3 are approved to treat breast cancer. This paper reviews the research progress of ADCs in the treatment of breast cancer in recent years.